Akua Owusu, MD
Psychiatry · Jacksonville, FLNPI 1104962257
Payments from drug & device makers
Across 320 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$830
- Teva Pharmaceuticals USA, Inc.$662
- Johnson & Johnson$619
- Otsuka America Pharmaceutical, Inc.$468
- Neurocrine Biosciences, Inc.$389
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,69498%
- Education$1092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,055 |
| Alkermes, Inc. | 33 | $830 |
| Teva Pharmaceuticals USA, Inc. | 50 | $662 |
| Johnson & Johnson | 32 | $619 |
| Otsuka America Pharmaceutical, Inc. | 26 | $468 |
| Neurocrine Biosciences, Inc. | 26 | $389 |
| Vanda Pharmaceuticals Inc. | 20 | $367 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $329 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $282 |
| Supernus Pharmaceuticals, Inc. | 8 | $186 |
| Sunovion Pharmaceuticals Inc. | 11 | $164 |
| Indivior Inc. | 5 | $106 |
| Axsome Therapeutics, Inc. | 5 | $94 |
| Corium, LLC | 4 | $56 |
| Lundbeck LLC | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Gilead | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$495
- VRAYLAR$244
- ARISTADA INITIO$124
- VIVITROL$119
How this compares
$5,803 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 19 | $158,867 |
| Invega TrinzaPaliperidone Palmitate | 12 | $76,197 |
| CaplytaLumateperone Tosylate | 16 | $27,560 |
| RexultiBrexpiprazole | 16 | $23,534 |
| VraylarCariprazine Hcl | 11 | $15,095 |
| TrintellixVortioxetine Hydrobromide | 11 | $13,269 |
| Clozapine | 34 | $6,018 |
| Aripiprazole | 52 | $3,998 |
| Vilazodone Hcl | 40 | $3,805 |
| Quetiapine Fumarate | 166 | $3,502 |
| Divalproex Sodium ErDivalproex Sodium | 40 | $3,315 |
| Guanfacine Hcl ErGuanfacine Hcl | 65 | $3,264 |
| Trazodone Hcl | 151 | $2,793 |
| Atomoxetine Hcl | 19 | $2,739 |
| Chlorpromazine Hcl | 13 | $2,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $662 | $158,86719 claims |
| Johnson & JohnsonInvega Trinza | $619 | $76,19712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $329 | $27,56016 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $468 | $23,53416 claims |
| AbbVieVraylar | $1,055 | $15,09511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $282 | $13,26911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Jacksonville
- John JoyceJacksonville$13.6M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.